Successful suspension-based viral vector manufacturing scale-up from process development to clinic

Cell & Gene Therapy Insights 2022; 8(8), 1215

DOI: 10.18609/cgti.2022.180

Published: 7 December 2022
Denis Kole, Timothy P Cripe, Lenore Giannunzio, Cassie-Marie Peigné

Cell and gene therapies have emerged as promising treatments for previously untreatable diseases, with viral vectors being used as the current preferred delivery vehicle. Safe, robust, and cost-effective vector manufacturing processes are necessary to support the demands of the patient population. Here, expert therapy developers, solutions providers, and CDMOs discuss considerations for the successful scale-up of viral vector processes from bench to commercial manufacturing.